Point72 Asset Management L.P. bought a new position in shares of Affimed NV (NASDAQ:AFMD) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 292,631 shares of the biopharmaceutical company’s stock, valued at approximately $658,000. Point72 Asset Management L.P. owned 0.66% of Affimed at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in AFMD. Dimensional Fund Advisors LP grew its holdings in Affimed by 817.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 137,783 shares of the biopharmaceutical company’s stock valued at $310,000 after buying an additional 122,773 shares in the last quarter. Virtu KCG Holdings LLC purchased a new position in shares of Affimed during the 2nd quarter worth $144,000. Finally, Nationwide Fund Advisors grew its holdings in shares of Affimed by 4.6% during the 2nd quarter. Nationwide Fund Advisors now owns 506,199 shares of the biopharmaceutical company’s stock worth $1,038,000 after purchasing an additional 22,172 shares during the period. 40.34% of the stock is owned by institutional investors and hedge funds.
Several equities analysts recently issued reports on the company. Oppenheimer reissued a “hold” rating on shares of Affimed in a research note on Friday, November 24th. ValuEngine lowered Affimed from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.
WARNING: “Point72 Asset Management L.P. Invests $658,000 in Affimed NV (AFMD)” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.com-unik.info/2017/12/24/point72-asset-management-l-p-invests-658000-in-affimed-nv-afmd.html.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.